Bori.Ns
Bharat Biotech is a biotechnology company that develops, manufactures, and markets vaccines and biologics, primarily in the Indian market.
Business. Bharat Biotech is a biotechnology company that develops, manufactures, and markets vaccines and biologics, primarily in the Indian market.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Bharat Biotech is a biotechnology company that develops, manufactures, and markets vaccines and biologics, primarily in the Indian market.
Bharat Biotech maintains a strong liquidity position, with a current ratio of 3.56, indicating the company can cover its short-term liabilities more than three times over. However, the company has a net cash position that is negative after subtracting total debt, signaling potential liquidity constraints in the near term. The debt-to-equity ratio of 0.04 suggests a conservative capital structure, with minimal reliance on debt financing.
In terms of profitability, Bharat Biotech's return on equity (ROE) of 6.63% and return on assets (ROA) of 5.27% are below the industry median for medical equipment and biotech firms, which typically report ROE and ROA in the 8-12% and 6-10% ranges, respectively. This suggests that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization.
The company's revenue is concentrated in a few key segments, with the majority of its sales derived from vaccine and biologics products. Geographically, the company is heavily reliant on the Indian market, with over 95% of its revenue generated domestically. This concentration increases exposure to regulatory and macroeconomic risks in India, particularly in the healthcare sector.
Looking ahead, Bharat Biotech is expected to see a modest increase in revenue in the current fiscal year, with a projected growth rate of 4-6% year-over-year. This growth is driven by the continued demand for its vaccines and the expansion of its product portfolio. However, the company faces challenges in scaling its international operations, which remain a small portion of its overall revenue.
The company's risk profile is characterized by medium liquidity risk and low dilution risk. The risk assessment indicates that while the company has sufficient short-term liquidity, its net cash position is negative after accounting for total debt, which could pose a constraint in the event of unexpected cash flow disruptions. Additionally, the company has not issued any new shares in the past 12 months, and there is no indication of dilution pressure in the near term.
Recent events include the company's continued focus on R&D and the launch of new vaccines, including a dengue vaccine and a malaria vaccine candidate. These developments are expected to support long-term growth and diversification of the product portfolio. The company has also been active in expanding its manufacturing capacity to meet growing demand, particularly in the domestic market.
- Bharat Biotech has a strong current ratio of 3.56, indicating robust short-term liquidity.
- The company's ROE of 6.63% and ROA of 5.27% are below industry medians, suggesting underperformance in capital efficiency.
- Revenue is heavily concentrated in the Indian market and vaccine products, increasing exposure to domestic regulatory and macroeconomic risks.
- The company is expected to see modest revenue growth in the current fiscal year, driven by new product launches and expanded manufacturing.
- Liquidity risk is medium, and dilution risk is low, with no new share issuance in the past 12 months.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- BORI.NS Market data — financials · 2026-05-27